EGFR突变型小细胞肺癌表现出异质性表型并对常见抗肿瘤药物耐药
研究从EGFR-TKI治疗失败的肺腺癌患者中建立两株EGFR突变型小细胞肺癌细胞系,发现其呈悬浮与贴壁两种表型,基因表达谱不同于非小细胞肺癌和经典型小细胞肺癌;EGFR-TKI联合AKT抑制剂可降低细胞活力,组蛋白去乙酰化酶抑制剂在体外和体内均显著抑制两株细胞系活力。
要点
- 两株EGFR突变型小细胞肺癌细胞系呈悬浮与贴壁两种不同表型。
- 贴壁细胞中EGFR和间充质标志物表达增加,神经内分泌标志物表达降低。
- EGFR-TKI联合AKT抑制剂或组蛋白去乙酰化酶抑制剂可降低细胞活力。
核心结论
- 作者认为EGFR突变型小细胞肺癌可能是具有上皮-间充质转化表型的独特小细胞肺癌亚类。
- 作者提出在现有治疗基础上加用AKT抑制剂或组蛋白去乙酰化酶抑制剂可能是转化型EGFR突变型小细胞肺癌的治疗选择之一。
研究设计与样本
- 从EGFR-TKI治疗失败的肺腺癌患者中建立两株EGFR突变型小细胞肺癌细胞系,以研究其分子基础与潜在治疗策略。
主要发现
- 两株细胞系呈悬浮与贴壁两种不同表型,基于微阵列的比较基因组杂交分析显示两者共享相同的基因组改变。
- 贴壁细胞中观察到EGFR和间充质标志物表达增加、神经内分泌标志物表达降低。
- RNA微阵列的主成分分析和层次聚类分析显示,两株细胞系的基因表达模式独特,明显不同于非小细胞肺癌和经典型小细胞肺癌细胞。
- EGFR-TKI联合AKT抑制剂减弱了两株细胞系的细胞活力。
- 组蛋白去乙酰化酶抑制剂在体外和体内均显著抑制两株细胞系的细胞活力。
临床怎么用
- 作者提出在现有治疗基础上加用AKT抑制剂或组蛋白去乙酰化酶抑制剂可能是转化型EGFR突变型小细胞肺癌的治疗选择之一。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Approximately 5% of patients with EGFR-activating mutations acquire EGFR tyrosine kinase inhibitor (TKI) resistance through SCLC transformation. However, the reason for the poor outcome and the molecular basis of EGFR-mutant SCLC that has transformed from adenocarcinoma remain unclear. METHODS: In this study, we established two EGFR-mutant SCLC cell lines from lung adenocarcinoma patients after failed EGFR-TKI treatment to investigate their molecular basis and potential therapeutic strategies in the hope of improving patient outcome. RESULTS: These two EGFR-mutant SCLC cell lines displayed two different phenotypes: suspensive and adherent. Both phenotypes shared the same genomic alterations analyzed by array-based comparative genomic hybridization assay. Increased expression of EGFR and mesenchymal markers and decreased expression of neuroendocrine markers were observed in adherent cells. Principal component analysis and hierarchical clustering analysis of RNA microarray revealed that these two cell lines displayed a unique gene expression pattern that was distinctly different from that in NSCLC and classical SCLC cells. Combined treatment using an EGFR-TKI and an AKT inhibitor attenuated cell viabilities in our two cell lines. Moreover, the use of a histone deacetylase inhibitor significantly inhibited the cell viabilities of both cell lines in vitro and in vivo. CONCLUSION: Our findings suggest that EGFR-mutant SCLC may be a distinct subclass of SCLC that exhibits epithelial-mesenchymal transition phenotypes, and adding an AKT or histone deacetylase inhibitor to pre-existing therapies may be one of the therapeutic choices for transformed EGFR-mutant SCLC.
引用
- Lin CA, Yu SL, Chen HY, et al. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs. J Thorac Oncol. 2018. PMID: 30521971. doi:10.1016/j.jtho.2018.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。